REGENXBIO, Inc. (RGNX)
8.94
-0.26
(-2.83%)
USD |
NASDAQ |
Sep 04, 16:00
8.925
-0.02
(-0.17%)
After-Hours: 20:00
REGENXBIO Research and Development Expense (Quarterly) : 52.33M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.33M |
| March 31, 2026 | 53.48M |
| December 31, 2025 | 55.74M |
| September 30, 2025 | 52.22M |
| June 30, 2025 | 55.60M |
| March 31, 2025 | 49.13M |
| December 31, 2024 | 46.36M |
| September 30, 2024 | 50.47M |
| June 30, 2024 | 44.82M |
| March 31, 2024 | 50.66M |
| December 31, 2023 | 51.35M |
| September 30, 2023 | 53.81M |
| June 30, 2023 | 55.45M |
| March 31, 2023 | 54.34M |
| December 31, 2022 | 58.38M |
| September 30, 2022 | 59.76M |
| June 30, 2022 | 58.36M |
| March 31, 2022 | 53.04M |
| December 31, 2021 | 45.37M |
| September 30, 2021 | 45.03M |
| June 30, 2021 | 43.68M |
| March 31, 2021 | 37.79M |
| December 31, 2020 | 45.08M |
| September 30, 2020 | 41.79M |
| Date | Value |
|---|---|
| June 30, 2020 | 35.98M |
| March 31, 2020 | 35.04M |
| December 31, 2019 | 31.88M |
| September 30, 2019 | 33.83M |
| June 30, 2019 | 29.48M |
| March 31, 2019 | 25.20M |
| December 31, 2018 | 24.33M |
| September 30, 2018 | 18.51M |
| June 30, 2018 | 21.49M |
| March 31, 2018 | 19.55M |
| December 31, 2017 | 14.17M |
| September 30, 2017 | 12.52M |
| June 30, 2017 | 13.92M |
| March 31, 2017 | 16.62M |
| December 31, 2016 | 16.06M |
| September 30, 2016 | 12.56M |
| June 30, 2016 | 10.68M |
| March 31, 2016 | 6.183M |
| December 31, 2015 | 4.812M |
| September 30, 2015 | 5.664M |
| June 30, 2015 | 4.012M |
| March 31, 2015 | 2.791M |
| March 31, 2014 | 0.937M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.344B |
| Capricor Therapeutics, Inc. | 28.57M |
| United Therapeutics Corp. | 146.30M |
| Ardelyx, Inc. | 25.50M |
| Biomea Fusion, Inc. | 9.142M |